How the study of helicobacter infection can contribute to the understanding of carcinoma development

Clinical Microbiology and Infection

Volumn 15, Issue 9, 2009, Pages 813-822

  Stoicov, C ^a   Li, H ^a   Cerny, J ^a   Houghton, Jean Marie ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Carcinoma development; Gastric cancer; Helicobacter infection; Stem cell; Stromal cells

Indexed keywords

CAGA PROTEIN; CHEMOKINE RECEPTOR CXCR4; FAS LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SECRETION; DNA DAMAGE; HELICOBACTER INFECTION; HOST PATHOGEN INTERACTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

HELICOBACTER;

EID: 69249121691     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02965.x     Document Type: Review

References (105)

1. IARC. Monographs on the evaluation of carcinogenic risks to humans, Vol. 61. Lyon: World Health Organization, 1994; 177-240.
2. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315.
3. Marshall BJ, Windsor HM. The relation of Helicobacter pylori of gastric adenocarcinoma and lymphoma: Pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am 2005; 89: 313-344.
4. Mahdavi J, Sonden B, Hurtig M et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297: 573-578.
5. Peek RM, Blaser M. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Rev Cancer 2002; 2: 28-37.
6. Ohnishi N et al. Transgenic expression of Helicobacter pylori: CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA 2008; 105: 1003-8.
7. Fox JG et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy. Nat Med 2000; 6: 536-539.
8. Stoicov C et al. Coinfection modulates inflammatory responses and clinical outcome of Helicobacter felis and Toxoplasma gondii infections. J Immunol 2004; 173: 3329-3336.
9. Bamford KB et al. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 1988; 114: 482-487.
10. Mohammadi M, Nedrud J, Redline R, Lycke N, Czinn SJ. Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology 1997; 113: 1848-1852.
11. Mohammadi M, Czinn S, Redline R, Nedrud J. Helicobacter-specific cell-mediated immune responses display a predominant TH1 phenotype and promote a delayed-type hypersensitive response in the stomachs of mice. J Immunol 1996; 156: 4729-4735.
12. El-Omar EM et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-1201.
13. Houghton J, Korah R, Condon M, Kim K. Apoptosis in H. pylori associated gastric and duodenal ulcer disease is mediated by the Fas antigen pathway. Dig Dis Sci 1999; 44: 465-478.
14. Houghton J, Macera-Bloch L, Harrison L, Korah R. TNF-α and IL-1β upregulate gastric mucosal Fas Ag expression in Helicobacter pylori infection. Infect Immun 2000; 68: 1189-1195.
15. Houghton J, Macera-Bloch L, Goldstein M, Von HagenS, Korah R. In vivo disruption of the Fas pathway abrogates gastric growth alterations secondary to Helicobacter infection. J Infect Dis 2000; 182: 856-864.
16. Li H, Cai X, Fan X, Moquin B, Stoicov C, Houghton J. Fas Ag-FasL coupling leads to ERK1/2-mediated proliferation of gastric mucosal cells. Am J Physiol Gastrointest Liver Physiol 2008; 294: G263-G275.
17. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 539-545.
18. Rather LJ. The Genesis of cancer: A study in the history of ideas. Baltimore: The Johns Hopkins University Press, 1978; 1-178.
19. Ford CE, Hamerton JL, Barnes DW, Loutit JF. Cytological identification of radiation-chimaeras. Nature 1956; 177: 452-454.
20. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14: 213-222.
21. Siminovitch L, McCulloch EA, Till JE. The distribution of colony-forming cells among spleen colonies. J Cell Physiol 1963; 62: 327-336.
22. Potten CS, Loeffle M. Stem cells: Attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110: 1001-1020.
23. Marshak DR ed. Introduction: Stem cell biology. Woodbury, NY: CSHL Press, 2001.
24. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241: 58-62.
25. Pierce GB. Neoplasms, differentiations and mutations. Am J Pathol 1974; 77: 103-118.
26. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
27. Singh SK et.al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
28. Singh SK et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
29. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811-822.
30. Fang D et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-9337.
31. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
32. Gibbs CP et al. Stem-like cells in bone sarcomas: Implications for tumorigenesis. Neoplasia 2005; 7: 967-976.
33. Barozzi P et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 5: 554-561.
34. Chakraborty A et al. Donor DNA in a renal cell carcinoma metastasis from a bone marrow transplant recipient. Bone Marrow Transplant 2004; 34: 183-186.
35. Aractingi S et al. Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res 2005; 65: 1755-1760.
36. Morath C et al. Transmission of donor derived small cell carcinoma cells by a nontumor bearing allograft. Transplantation 2005; 80: 540-541.
37. Golfinopouloss V et al. Donor derived breast cancer in a bone marrow transplantation recipient. Breast Cancer Res Treat 2009; 113: 211-213.
38. Houghton J et al. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306: 1568-1571.
39. Li H et al. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells; a model of age-related tumorigenesis in mice. Cancer Res 2007; 67: 10889-10898.
40. Peters BA et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11: 261-262.
41. Dome B et al. Identification and clinical significance of circulating endothelial progenitor cells in human non small cell lung cancer. Cancer Res 2006; 66: 7341-7347.
42. Ho JW et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006; 44: 836-843.
43. Karnoub AE et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563.
44. Kaplan RN et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005; 438: 820-827.
45. El-Omar EM et al. Interleukin 1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
46. Roberts RA, Kimber I. Cytokines in non-genotoxic hepatocarcinogenesis. Carcinogenesis 1999; 20: 1397-1401.
47. Tanaka Y et al. Impact of interleukin 1-beta genetic polymorphism on the development of hepatitis C virus related hepatocellular carcinoma in Japan. J Infect Dis 2003; 187: 1882-1825.
48. Nozaki K et al. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology 2008; 134: 511-522.
49. Morrison SJ, Kimble J. Asymmetric and symmetric stem cell divisions in development and cancer. Nature 2006; 441: 1068-1074.
50. Bryder D, Rossi DJ, Weissman IL. Biological perspectives- Hematopoietic stem cells. The paradigmatic tissue specific stem cell. Am J Pathol 2006; 169: 338-346.
51. Sharpless NE, DePinho RA. Telomeres stem cell senescence and cancer. J Clin Invest 2004; 113: 160-168.
52. Ruzankina Y et al. Deletion of the developmentally essential gene Atr in adult mice leads to age related phenotypes and stem cell loss. Cell Stem Cell 2007; 1: 113-126.
53. Houghton J. Bone-marrow-derived cells and cancer-an opportunity for improved therapy. Nat Clin Pract Oncol 2007; 4: 2-3.
54. Greten FR, Karin M. The IKK/NF-kappaB activation pathway a target for prevention and treatment of cancer. Cancer Lett 2004; 206: 193-199.
55. Maeda A et al. Primary liver cancer with bidirectional differentiation into hepatocytes and biliary epithelium. J Hepatobiliary Pancreat Surg 2005; 12: 484-487.
56. Droll L et al. TNFaβ protects tissue resident stem cells from H2O2 induced apoptosis through a novel NF-κB p50/p50 homodimer mediated signaling pathway. Biochem Biophys Res Commu 2008; 371: 626-629.
57. Crisostomo PR 1 et al. Human mesenchymal stem cells stimulated by TNF, LPS or hypoxia produced growth factors by an NF-κB but not JNK dependent mechanism. Am J Physiol Cell Physiol 2008; 294: C675-C682.
58. Kollias G, Douni E, Kassoitis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999; 169: 175-194.
59. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998; 10: 573-580.
60. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumor necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998; 77: 2246-2251.
61. Malik STA, Griffin DB, Fiers W, Balkwill FR. Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int J Cancer 1989; 44: 918-925.
62. Malik STA, Naylor S, East N, Oliff A, Balkwill FR. Cells secreting tumor necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990; 26: 1031-1034.
63. O'Bryne KJ, Dalgleish AG, Browing MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000; 36: 151-169.
64. Grayson WL, Feng Z, Bunnell B, Teng M. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 2007; 358: 948-953.
65. Francis EL, Rohan TE. Cancer precursors-epidemiology detection and prevention. New York: Springer Press, 2002. (Not in PubMed).
66. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-6740.
67. Fox JG, Wang TC. Inflammation atrophy and gastric cancer. J Clin Invest 2006; 117: 60-69.
68. Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology 2005; 128: 1937-1952.
69. Faller G, Kirchner T. Immunological and morphogenic basis of gastric mucosa atrophy and metaplasia. Virchows Arch 2005; 446: 1-9.
70. Whitcomb DC. Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2004; 287: G315-G319.
71. De Marzo AM, Nakai Y, Nelson WG. Inflammation atrophy and prostate carcinogenesis. Urol Oncol 2007; 25: 398-400.
72. Olaso E et al. Tumor dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. Hepatology 1997; 26: 634-642.
73. Olaso E et al. Proangiogenic role of tumor activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 2003; 37: 674-685.
74. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-1375.
75. Nagasawa T et al. Defects of B-cell lymphopoiesis and bone marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-638.
76. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999; 10: 463-471.
77. Bagri A et al. The chemokine SDF-1 regulates migration of dentate granule cells. Development 2002; 129: 4249-4260.
78. Kucia M, Ratajczak MZ. Bone marrow as a source of circulating CXCR4+ tissue committed stem cells (TCSC). Biol Cell 2005; 97: 133-146.
79. Petit I et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up regulating CXCR4. Nat Immunol 2002; 3: 687-694.
80. Liles WC et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD31000, a CXCR4 antagonist. Blood 2003; 102: 2728-2730.
81. Devine SM et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non Hodgkins lymphoma. J Clin Oncol 2004; 22: 1095-1102.
82. Helbig G et al. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003; 278: 21631-21638.
83. Schioppa T et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198: 1391-1402.
84. Franitza S et al. TGF-beta1 enhances SDF-1 alpha induced chemotaxis and homing of naïve T cells by upregulating CXCR4 expression and downstream cytoskeletal effector molecules. Eur J Immunol 2002; 32: 109-202.
85. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002; 62: 7203-7206.
86. Yonezawa A et al. Natural alpha interferon producing cells respond to human immumodeficiency virus type I with alpha interferon production and maturation into dendritic cells. J Virol 2003; 77: 3777-3784.
87. Iikura M et al. Chemokine receptors in human basophils: Inducible and functional CXCR4. J Leukoc Biol 2001; 70: 113-120.
88. Jourdan P et.al. Cytokine and cell surface molecules independently induce CXCR4 expression on CD4+ CCR7+ human memory T cells. J Immunol 2000; 165: 716-724.
89. Wysoczynski M et al. Incorporation of CXCR4 into membrane lipid rafts primes homing related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 2005; 105: 40-48.
90. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10-19.
91. Schmidmaier R et al. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranygeranylation of Rho protein and activation of Rho kinase. Blood 2004; 104: 25-32.
92. Christopherson KW et al. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305: 1000-1003.
93. Peled A et.al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: Role in transendothelial stromal migration and engraftment of NOD/SCID mice. Blood 2000; 95: 3289-3296.
94. Janowska-Wieczorek A et al. Differential MMP and TIMP production by human marrow and peripheral blood CD34+ cells in response to chemokines. Exp Hematol 2000; 28: 1274-1285.
95. Kijowski J et al. The SDF-1 CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. Stem Cells 2001; 19: 453-466.
96. Kucia M et al. CXCR4-SDF-1 signaling locomotion chemotaxis and adhesion. J Mol Histol 2004; 3: 233-245.
97. Libura J et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion chemotaxis and adhesion. Blood 2002; 100: 2597-2606.
98. Dontu G et al. Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36: 59-72.
99. Muller A et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
100. Sun XX et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (Pca) in vivo. J Cell Biochem 2003; 89: 462-473.
101. Geminder H et al. A possible role for CXCR4 and its ligand the CXC chemokine stromal cell derived factor 1 in the development of bone marrow metastases in neuroblastoma. J Immunol 2001; 167: 4747-4757.
102. Porcile C et al. CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Ann NY Acad Sci 2004; 1030: 162-169.
103. Hall JM, Korache KS. Stromal cell derived factor 1 a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cell. Mol Endocrinol 2003; 17: 792-803.
104. Jankowski K et al. Both hepatocyte growth factor (HGF) and stromal derived factor 1 regulate the metastatic behavior of human rhabdomyosarcoma cells but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003; 63: 7926-7935.
105. Kollet O et al. HGF, SDF-1 and MMP-9 are involved in stress induced human CD34+ stem cell recruitment to the liver. J Clin Invest 2003; 112: 160-169.